| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpes Zoster | 24 | 2024 | 88 | 10.450 |
Why?
|
| Herpes Zoster Vaccine | 19 | 2024 | 64 | 8.880 |
Why?
|
| Vaccination | 33 | 2024 | 674 | 4.880 |
Why?
|
| Herpesvirus 3, Human | 13 | 2024 | 49 | 3.350 |
Why?
|
| Meningococcal Vaccines | 5 | 2020 | 46 | 3.160 |
Why?
|
| Humans | 117 | 2024 | 18430 | 2.980 |
Why?
|
| Hospitalization | 14 | 2024 | 847 | 2.790 |
Why?
|
| Chickenpox Vaccine | 11 | 2016 | 101 | 2.360 |
Why?
|
| Male | 76 | 2024 | 10440 | 2.330 |
Why?
|
| Cohort Studies | 31 | 2023 | 2672 | 2.280 |
Why?
|
| Female | 77 | 2024 | 13136 | 2.220 |
Why?
|
| California | 33 | 2024 | 2365 | 2.210 |
Why?
|
| Aged | 47 | 2024 | 6417 | 2.200 |
Why?
|
| Meningococcal Infections | 3 | 2020 | 17 | 2.120 |
Why?
|
| Chickenpox | 10 | 2016 | 38 | 2.100 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 5 | 2022 | 95 | 2.040 |
Why?
|
| Influenza, Human | 4 | 2024 | 282 | 1.970 |
Why?
|
| Middle Aged | 52 | 2024 | 8284 | 1.900 |
Why?
|
| Pneumococcal Vaccines | 6 | 2022 | 80 | 1.740 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2021 | 24 | 1.640 |
Why?
|
| Neuralgia, Postherpetic | 3 | 2024 | 15 | 1.600 |
Why?
|
| Adolescent | 33 | 2023 | 3798 | 1.580 |
Why?
|
| Adult | 48 | 2024 | 7910 | 1.570 |
Why?
|
| Influenza Vaccines | 5 | 2024 | 290 | 1.520 |
Why?
|
| Neisseria meningitidis | 2 | 2020 | 11 | 1.450 |
Why?
|
| Child | 32 | 2023 | 2571 | 1.390 |
Why?
|
| Taiwan | 28 | 2010 | 33 | 1.380 |
Why?
|
| Aged, 80 and over | 19 | 2024 | 2003 | 1.320 |
Why?
|
| Retrospective Studies | 18 | 2024 | 2550 | 1.300 |
Why?
|
| Child, Preschool | 24 | 2020 | 1478 | 1.250 |
Why?
|
| Diphtheria | 2 | 2022 | 14 | 1.250 |
Why?
|
| Tetanus | 2 | 2022 | 18 | 1.250 |
Why?
|
| Infant | 23 | 2022 | 1245 | 1.240 |
Why?
|
| United States | 19 | 2024 | 4164 | 1.230 |
Why?
|
| Whooping Cough | 3 | 2022 | 75 | 1.200 |
Why?
|
| Immunization, Secondary | 5 | 2016 | 64 | 1.120 |
Why?
|
| Incidence | 18 | 2023 | 1314 | 1.110 |
Why?
|
| Managed Care Programs | 5 | 2017 | 347 | 1.050 |
Why?
|
| Young Adult | 18 | 2021 | 2518 | 1.030 |
Why?
|
| Health Care Costs | 2 | 2020 | 251 | 0.920 |
Why?
|
| Vaccines | 6 | 2019 | 222 | 0.920 |
Why?
|
| Nervous System Diseases | 3 | 2020 | 20 | 0.910 |
Why?
|
| Vaccination Coverage | 1 | 2024 | 45 | 0.910 |
Why?
|
| Hepatitis B Vaccines | 3 | 2014 | 46 | 0.880 |
Why?
|
| Antibodies, Viral | 4 | 2011 | 65 | 0.870 |
Why?
|
| Case-Control Studies | 10 | 2023 | 1173 | 0.860 |
Why?
|
| Vaccines, Conjugate | 6 | 2022 | 66 | 0.830 |
Why?
|
| Risk Factors | 20 | 2020 | 3449 | 0.820 |
Why?
|
| Age Factors | 11 | 2020 | 965 | 0.790 |
Why?
|
| Hepatitis B | 2 | 2014 | 43 | 0.770 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 6 | 0.750 |
Why?
|
| Program Evaluation | 7 | 2006 | 244 | 0.740 |
Why?
|
| Skin Diseases | 1 | 2020 | 10 | 0.730 |
Why?
|
| Recurrence | 2 | 2020 | 187 | 0.730 |
Why?
|
| Multiple Sclerosis | 2 | 2014 | 97 | 0.720 |
Why?
|
| Coinfection | 1 | 2020 | 30 | 0.720 |
Why?
|
| Pneumococcal Infections | 3 | 2022 | 53 | 0.700 |
Why?
|
| Immunization Programs | 4 | 2013 | 68 | 0.700 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 70 | 0.690 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2019 | 14 | 0.690 |
Why?
|
| Prospective Studies | 6 | 2023 | 1314 | 0.680 |
Why?
|
| Attitude of Health Personnel | 5 | 2009 | 226 | 0.670 |
Why?
|
| Infant, Newborn | 9 | 2022 | 872 | 0.660 |
Why?
|
| Pain | 1 | 2019 | 84 | 0.640 |
Why?
|
| Nurse Clinicians | 2 | 2010 | 3 | 0.640 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2020 | 159 | 0.630 |
Why?
|
| Vaccines, Synthetic | 3 | 2024 | 43 | 0.600 |
Why?
|
| HIV Infections | 1 | 2024 | 695 | 0.590 |
Why?
|
| Pregnancy | 6 | 2022 | 1516 | 0.590 |
Why?
|
| Medicare Part D | 1 | 2017 | 21 | 0.590 |
Why?
|
| Thyroid Hormones | 1 | 2017 | 8 | 0.590 |
Why?
|
| Cost Sharing | 1 | 2017 | 40 | 0.580 |
Why?
|
| Meningitis, Meningococcal | 1 | 2017 | 7 | 0.570 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 382 | 0.570 |
Why?
|
| Kidney Failure, Chronic | 2 | 2015 | 151 | 0.550 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 3 | 2017 | 101 | 0.540 |
Why?
|
| Policy Making | 1 | 2016 | 18 | 0.530 |
Why?
|
| Surveys and Questionnaires | 12 | 2016 | 1389 | 0.530 |
Why?
|
| Clinical Competence | 3 | 2005 | 108 | 0.520 |
Why?
|
| Immunocompetence | 4 | 2020 | 10 | 0.510 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2014 | 7 | 0.490 |
Why?
|
| Education, Nursing, Baccalaureate | 2 | 2005 | 2 | 0.490 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2017 | 412 | 0.470 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 65 | 0.460 |
Why?
|
| Seasons | 3 | 2024 | 105 | 0.450 |
Why?
|
| Population Surveillance | 5 | 2016 | 271 | 0.450 |
Why?
|
| Students, Nursing | 4 | 2006 | 5 | 0.450 |
Why?
|
| Empathy | 4 | 2006 | 7 | 0.440 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 118 | 0.430 |
Why?
|
| Seizures, Febrile | 4 | 2014 | 47 | 0.430 |
Why?
|
| Drug Utilization | 1 | 2013 | 134 | 0.430 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2014 | 12 | 0.420 |
Why?
|
| Risk | 7 | 2021 | 552 | 0.420 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 3 | 2017 | 33 | 0.400 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2009 | 392 | 0.400 |
Why?
|
| Students | 2 | 2009 | 54 | 0.390 |
Why?
|
| Self Efficacy | 2 | 2009 | 71 | 0.380 |
Why?
|
| Nursing Diagnosis | 1 | 2010 | 1 | 0.370 |
Why?
|
| Employee Performance Appraisal | 1 | 2010 | 6 | 0.370 |
Why?
|
| Thinking | 1 | 2010 | 4 | 0.370 |
Why?
|
| Anus Neoplasms | 2 | 2017 | 26 | 0.370 |
Why?
|
| Professional Competence | 1 | 2010 | 12 | 0.370 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2020 | 17 | 0.370 |
Why?
|
| Myasthenia Gravis | 1 | 2010 | 1 | 0.360 |
Why?
|
| Mortality | 2 | 2021 | 123 | 0.360 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2010 | 3 | 0.360 |
Why?
|
| Disease Notification | 2 | 2009 | 7 | 0.350 |
Why?
|
| Prepaid Health Plans | 1 | 2009 | 22 | 0.350 |
Why?
|
| Time Factors | 5 | 2020 | 1136 | 0.350 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2009 | 1 | 0.340 |
Why?
|
| Neoplasms | 1 | 2014 | 457 | 0.330 |
Why?
|
| Genome, Viral | 3 | 2020 | 4 | 0.330 |
Why?
|
| Private Practice | 1 | 2009 | 15 | 0.330 |
Why?
|
| Universities | 1 | 2009 | 15 | 0.330 |
Why?
|
| Communicable Diseases | 1 | 2009 | 15 | 0.330 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 2 | 2022 | 19 | 0.320 |
Why?
|
| Motor Neuron Disease | 1 | 2008 | 1 | 0.320 |
Why?
|
| Natural Language Processing | 2 | 2019 | 57 | 0.320 |
Why?
|
| RNA, Ribosomal | 1 | 2008 | 1 | 0.310 |
Why?
|
| Faculty, Nursing | 2 | 2005 | 3 | 0.310 |
Why?
|
| Myocardial Infarction | 1 | 2010 | 249 | 0.310 |
Why?
|
| Encephalitis Virus, Japanese | 2 | 2005 | 2 | 0.300 |
Why?
|
| Encephalitis, Japanese | 2 | 2005 | 2 | 0.300 |
Why?
|
| Models, Nursing | 2 | 2005 | 3 | 0.300 |
Why?
|
| Physicians | 1 | 2009 | 141 | 0.300 |
Why?
|
| Databases, Factual | 3 | 2019 | 327 | 0.290 |
Why?
|
| Tai Ji | 1 | 2007 | 3 | 0.290 |
Why?
|
| Homes for the Aged | 1 | 2007 | 6 | 0.290 |
Why?
|
| Nursing Homes | 1 | 2007 | 10 | 0.290 |
Why?
|
| Primary Health Care | 1 | 2014 | 848 | 0.290 |
Why?
|
| National Health Programs | 2 | 2006 | 10 | 0.290 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2008 | 55 | 0.290 |
Why?
|
| Stroke | 1 | 2010 | 311 | 0.290 |
Why?
|
| Community-Acquired Infections | 2 | 2018 | 24 | 0.290 |
Why?
|
| Seroepidemiologic Studies | 5 | 2007 | 20 | 0.290 |
Why?
|
| Anaphylaxis | 2 | 2019 | 15 | 0.280 |
Why?
|
| Risk Assessment | 6 | 2015 | 1143 | 0.280 |
Why?
|
| Mass Vaccination | 2 | 2005 | 22 | 0.280 |
Why?
|
| Rubella virus | 1 | 2006 | 1 | 0.270 |
Why?
|
| Rubella Vaccine | 1 | 2006 | 9 | 0.270 |
Why?
|
| Rubella | 1 | 2006 | 6 | 0.270 |
Why?
|
| Nurse-Patient Relations | 2 | 2005 | 8 | 0.270 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 116 | 0.260 |
Why?
|
| Longitudinal Studies | 5 | 2012 | 724 | 0.260 |
Why?
|
| Patient Care Planning | 1 | 2005 | 51 | 0.260 |
Why?
|
| Age Distribution | 4 | 2015 | 261 | 0.250 |
Why?
|
| Sex Factors | 4 | 2014 | 661 | 0.250 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2015 | 14 | 0.250 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 743 | 0.250 |
Why?
|
| Disease Management | 1 | 2005 | 143 | 0.240 |
Why?
|
| Logistic Models | 4 | 2017 | 962 | 0.240 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2006 | 142 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 131 | 0.230 |
Why?
|
| Insurance, Health | 1 | 2006 | 217 | 0.230 |
Why?
|
| Patient Education as Topic | 1 | 2005 | 214 | 0.230 |
Why?
|
| Education, Professional, Retraining | 1 | 2003 | 1 | 0.230 |
Why?
|
| RNA, Messenger | 2 | 2023 | 80 | 0.230 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2003 | 1 | 0.230 |
Why?
|
| China | 1 | 2024 | 130 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 270 | 0.230 |
Why?
|
| Vaccines, Combined | 1 | 2024 | 91 | 0.230 |
Why?
|
| Curriculum | 1 | 2003 | 40 | 0.230 |
Why?
|
| Down Syndrome | 1 | 2023 | 4 | 0.220 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2023 | 14 | 0.220 |
Why?
|
| Quality of Life | 1 | 2007 | 529 | 0.220 |
Why?
|
| Treatment Outcome | 3 | 2016 | 1296 | 0.210 |
Why?
|
| Burns, Chemical | 1 | 2022 | 1 | 0.210 |
Why?
|
| Chemical Warfare Agents | 1 | 2022 | 1 | 0.210 |
Why?
|
| Mustard Gas | 1 | 2022 | 1 | 0.210 |
Why?
|
| Corynebacterium | 1 | 2022 | 3 | 0.210 |
Why?
|
| Sexual Behavior | 1 | 2003 | 123 | 0.210 |
Why?
|
| Immunization Schedule | 2 | 2021 | 133 | 0.210 |
Why?
|
| Rotavirus Vaccines | 1 | 2022 | 50 | 0.210 |
Why?
|
| Placenta | 1 | 2022 | 20 | 0.210 |
Why?
|
| Polymerase Chain Reaction | 5 | 2020 | 53 | 0.200 |
Why?
|
| Odds Ratio | 4 | 2018 | 701 | 0.200 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 15 | 0.190 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 1269 | 0.190 |
Why?
|
| Budgets | 1 | 2020 | 5 | 0.190 |
Why?
|
| Orthomyxoviridae | 1 | 2020 | 5 | 0.180 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 530 | 0.180 |
Why?
|
| Comorbidity | 2 | 2020 | 619 | 0.180 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 40 | 0.180 |
Why?
|
| Morbidity | 1 | 2020 | 62 | 0.180 |
Why?
|
| Tandem Repeat Sequences | 1 | 2020 | 1 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2015 | 407 | 0.180 |
Why?
|
| Patient Safety | 1 | 2020 | 41 | 0.170 |
Why?
|
| Vaccine Potency | 1 | 2019 | 5 | 0.170 |
Why?
|
| Premature Birth | 1 | 2021 | 138 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 342 | 0.160 |
Why?
|
| Genotype | 2 | 2017 | 253 | 0.160 |
Why?
|
| DNA, Viral | 2 | 2020 | 17 | 0.160 |
Why?
|
| Mouth Neoplasms | 2 | 2009 | 9 | 0.160 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 159 | 0.160 |
Why?
|
| Electronic Health Records | 3 | 2023 | 747 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2021 | 567 | 0.160 |
Why?
|
| Coccidioides | 1 | 2018 | 3 | 0.160 |
Why?
|
| Coccidioidomycosis | 1 | 2018 | 5 | 0.160 |
Why?
|
| Elder Abuse | 2 | 2009 | 3 | 0.160 |
Why?
|
| Papillomavirus Infections | 2 | 2017 | 136 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 38 | 0.150 |
Why?
|
| Family Health | 1 | 2017 | 49 | 0.150 |
Why?
|
| Phylogeny | 1 | 2017 | 14 | 0.150 |
Why?
|
| Genotyping Techniques | 1 | 2017 | 26 | 0.150 |
Why?
|
| Neurons | 1 | 2017 | 10 | 0.150 |
Why?
|
| Genomics | 1 | 2017 | 66 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2017 | 87 | 0.140 |
Why?
|
| Bell Palsy | 1 | 2017 | 17 | 0.140 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2016 | 5 | 0.140 |
Why?
|
| Myelitis, Transverse | 1 | 2016 | 5 | 0.140 |
Why?
|
| Papillomaviridae | 1 | 2017 | 53 | 0.140 |
Why?
|
| Psychometrics | 4 | 2010 | 124 | 0.140 |
Why?
|
| Prevalence | 2 | 2010 | 911 | 0.140 |
Why?
|
| Chi-Square Distribution | 3 | 2008 | 160 | 0.140 |
Why?
|
| Perioperative Period | 1 | 2016 | 5 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 444 | 0.130 |
Why?
|
| Cross Infection | 1 | 2015 | 28 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2015 | 59 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 22 | 0.130 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2013 | 110 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2011 | 414 | 0.130 |
Why?
|
| Factor Analysis, Statistical | 3 | 2010 | 36 | 0.130 |
Why?
|
| Japanese Encephalitis Vaccines | 2 | 2005 | 2 | 0.120 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 52 | 0.120 |
Why?
|
| Ethnic Groups | 3 | 2015 | 501 | 0.120 |
Why?
|
| Philosophy, Nursing | 2 | 2005 | 2 | 0.120 |
Why?
|
| Nursing Education Research | 2 | 2005 | 2 | 0.120 |
Why?
|
| Models, Educational | 2 | 2005 | 7 | 0.120 |
Why?
|
| Communication | 3 | 2006 | 202 | 0.120 |
Why?
|
| African Americans | 2 | 2017 | 490 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 20 | 0.120 |
Why?
|
| Oxidative Stress | 2 | 2006 | 10 | 0.120 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 6 | 0.120 |
Why?
|
| Serologic Tests | 1 | 2014 | 6 | 0.120 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 18 | 0.120 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 21 | 0.120 |
Why?
|
| Gonorrhea | 1 | 2014 | 19 | 0.120 |
Why?
|
| Chlamydia Infections | 1 | 2014 | 27 | 0.120 |
Why?
|
| Syphilis | 1 | 2014 | 17 | 0.120 |
Why?
|
| European Continental Ancestry Group | 3 | 2017 | 554 | 0.110 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2013 | 22 | 0.110 |
Why?
|
| Vaccines, Acellular | 1 | 2012 | 12 | 0.110 |
Why?
|
| Off-Label Use | 1 | 2012 | 14 | 0.110 |
Why?
|
| Animals | 3 | 2008 | 261 | 0.110 |
Why?
|
| Men's Health | 1 | 2012 | 20 | 0.100 |
Why?
|
| Exercise | 2 | 2008 | 495 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2012 | 52 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 399 | 0.100 |
Why?
|
| Breast Neoplasms | 2 | 2011 | 1037 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2010 | 1360 | 0.100 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2009 | 4 | 0.100 |
Why?
|
| Hypersensitivity | 1 | 2011 | 21 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2014 | 318 | 0.100 |
Why?
|
| Epistasis, Genetic | 1 | 2011 | 3 | 0.100 |
Why?
|
| Nursing Methodology Research | 3 | 2006 | 8 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 35 | 0.100 |
Why?
|
| Outpatients | 2 | 2015 | 111 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2011 | 85 | 0.090 |
Why?
|
| Mice | 2 | 2008 | 68 | 0.090 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2010 | 4 | 0.090 |
Why?
|
| Social Class | 1 | 2011 | 125 | 0.090 |
Why?
|
| Virus Activation | 1 | 2010 | 6 | 0.090 |
Why?
|
| Wine | 1 | 2010 | 18 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 9 | 0.090 |
Why?
|
| Sex Distribution | 2 | 2015 | 198 | 0.090 |
Why?
|
| International Classification of Diseases | 1 | 2010 | 87 | 0.090 |
Why?
|
| Acute Disease | 1 | 2010 | 144 | 0.090 |
Why?
|
| Genome, Human | 1 | 2009 | 42 | 0.090 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2009 | 1 | 0.090 |
Why?
|
| Matrix Metalloproteinase 10 | 1 | 2009 | 1 | 0.090 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2009 | 1 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2009 | 3 | 0.080 |
Why?
|
| Carrier State | 1 | 2009 | 8 | 0.080 |
Why?
|
| Muscle, Skeletal | 2 | 2006 | 32 | 0.080 |
Why?
|
| Stress, Psychological | 2 | 2009 | 147 | 0.080 |
Why?
|
| Nursing Evaluation Research | 2 | 2005 | 3 | 0.080 |
Why?
|
| Superoxide Dismutase | 2 | 2006 | 2 | 0.080 |
Why?
|
| Glutathione Peroxidase | 2 | 2006 | 3 | 0.080 |
Why?
|
| Menopause | 1 | 2009 | 72 | 0.080 |
Why?
|
| Decision Making | 1 | 2010 | 204 | 0.080 |
Why?
|
| Arginine | 1 | 2008 | 12 | 0.080 |
Why?
|
| Nitric Oxide | 1 | 2008 | 7 | 0.080 |
Why?
|
| Algorithms | 2 | 2011 | 241 | 0.080 |
Why?
|
| Genes, Neoplasm | 1 | 2008 | 4 | 0.080 |
Why?
|
| DNA Repair | 1 | 2008 | 10 | 0.080 |
Why?
|
| Cloning, Molecular | 1 | 2008 | 3 | 0.080 |
Why?
|
| DNA, Ribosomal | 1 | 2008 | 3 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2008 | 70 | 0.080 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2008 | 90 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 26 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 146 | 0.080 |
Why?
|
| Nursing | 1 | 2007 | 2 | 0.080 |
Why?
|
| Health Maintenance Organizations | 1 | 2010 | 479 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 20 | 0.080 |
Why?
|
| Continental Population Groups | 1 | 2010 | 315 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2008 | 100 | 0.080 |
Why?
|
| Health Planning | 1 | 2007 | 17 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2011 | 468 | 0.070 |
Why?
|
| Caregivers | 1 | 2009 | 126 | 0.070 |
Why?
|
| Life Style | 2 | 2009 | 342 | 0.070 |
Why?
|
| Bone Density | 1 | 2008 | 96 | 0.070 |
Why?
|
| Aging | 1 | 2008 | 165 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 96 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2007 | 82 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 298 | 0.070 |
Why?
|
| Asia | 1 | 2006 | 15 | 0.070 |
Why?
|
| Peer Group | 1 | 2006 | 48 | 0.070 |
Why?
|
| Vitamin E | 1 | 2006 | 20 | 0.070 |
Why?
|
| Physical Exertion | 1 | 2006 | 22 | 0.070 |
Why?
|
| Valerates | 1 | 2006 | 1 | 0.070 |
Why?
|
| Insurance Claim Review | 1 | 2006 | 70 | 0.070 |
Why?
|
| Diet, Diabetic | 1 | 2005 | 9 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2006 | 50 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 25 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 630 | 0.070 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2006 | 67 | 0.060 |
Why?
|
| Poisson Distribution | 2 | 2015 | 94 | 0.060 |
Why?
|
| Lung | 1 | 2006 | 62 | 0.060 |
Why?
|
| Codes of Ethics | 1 | 2005 | 1 | 0.060 |
Why?
|
| Clostridium difficile | 2 | 2015 | 23 | 0.060 |
Why?
|
| Rural Health Services | 1 | 2005 | 14 | 0.060 |
Why?
|
| Health Status | 1 | 2007 | 328 | 0.060 |
Why?
|
| Program Development | 1 | 2005 | 81 | 0.060 |
Why?
|
| Rural Population | 1 | 2005 | 52 | 0.060 |
Why?
|
| Health Plan Implementation | 1 | 2005 | 41 | 0.060 |
Why?
|
| Glycated Hemoglobin A | 1 | 2005 | 233 | 0.060 |
Why?
|
| Self Care | 1 | 2005 | 175 | 0.060 |
Why?
|
| Depression | 1 | 2009 | 518 | 0.060 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2005 | 254 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2006 | 266 | 0.060 |
Why?
|
| Educational Measurement | 1 | 2003 | 19 | 0.060 |
Why?
|
| Neutralization Tests | 1 | 2003 | 3 | 0.060 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 109 | 0.060 |
Why?
|
| Rural Health | 1 | 2003 | 8 | 0.060 |
Why?
|
| Urban Health | 1 | 2003 | 40 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 199 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 333 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2004 | 177 | 0.060 |
Why?
|
| Los Angeles | 1 | 2003 | 141 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 476 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2010 | 656 | 0.050 |
Why?
|
| Safety | 1 | 2003 | 45 | 0.050 |
Why?
|
| Vaccines, Attenuated | 1 | 2023 | 47 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2003 | 327 | 0.050 |
Why?
|
| Mechlorethamine | 1 | 2022 | 1 | 0.050 |
Why?
|
| Skin | 1 | 2022 | 14 | 0.050 |
Why?
|
| Rest | 1 | 2002 | 3 | 0.050 |
Why?
|
| Football | 1 | 2002 | 5 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 5 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2002 | 15 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 320 | 0.050 |
Why?
|
| Outpatient Clinics, Hospital | 2 | 2016 | 15 | 0.050 |
Why?
|
| Research Design | 1 | 2024 | 402 | 0.050 |
Why?
|
| Mass Screening | 1 | 2007 | 690 | 0.050 |
Why?
|
| Inpatients | 2 | 2015 | 80 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2020 | 2 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2014 | 319 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 44 | 0.050 |
Why?
|
| Protein Binding | 1 | 2020 | 9 | 0.050 |
Why?
|
| Infant, Premature | 1 | 2021 | 60 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2009 | 46 | 0.040 |
Why?
|
| Immunoassay | 1 | 2018 | 9 | 0.040 |
Why?
|
| Dietary Supplements | 2 | 2009 | 88 | 0.040 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2016 | 30 | 0.030 |
Why?
|
| Philadelphia | 1 | 2016 | 6 | 0.030 |
Why?
|
| Infection | 1 | 2016 | 17 | 0.030 |
Why?
|
| Social Support | 2 | 2009 | 214 | 0.030 |
Why?
|
| Disease Transmission, Infectious | 1 | 2016 | 13 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2017 | 112 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 60 | 0.030 |
Why?
|
| Hospitals | 1 | 2015 | 80 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 321 | 0.030 |
Why?
|
| Epilepsy | 1 | 2014 | 13 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 2 | 2006 | 2 | 0.030 |
Why?
|
| Qualitative Research | 2 | 2006 | 272 | 0.030 |
Why?
|
| Hispanic Americans | 1 | 2017 | 428 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2006 | 167 | 0.030 |
Why?
|
| Maternal Age | 1 | 2014 | 80 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 162 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 142 | 0.030 |
Why?
|
| Gestational Age | 1 | 2014 | 119 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 598 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 2 | 0.020 |
Why?
|
| Chromosomes, Human | 1 | 2011 | 2 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2011 | 7 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 11 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2011 | 24 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2008 | 974 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2009 | 28 | 0.020 |
Why?
|
| Medicine, Traditional | 1 | 2009 | 4 | 0.020 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2009 | 6 | 0.020 |
Why?
|
| Gingival Neoplasms | 1 | 2009 | 1 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 7 | 0.020 |
Why?
|
| Base Sequence | 1 | 2009 | 20 | 0.020 |
Why?
|
| ROC Curve | 1 | 2009 | 83 | 0.020 |
Why?
|
| Life Change Events | 1 | 2009 | 31 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 108 | 0.020 |
Why?
|
| Inservice Training | 1 | 2009 | 15 | 0.020 |
Why?
|
| Job Satisfaction | 1 | 2009 | 20 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2009 | 25 | 0.020 |
Why?
|
| Ammonia | 1 | 2008 | 1 | 0.020 |
Why?
|
| Lactates | 1 | 2008 | 2 | 0.020 |
Why?
|
| Martial Arts | 1 | 2008 | 2 | 0.020 |
Why?
|
| Citrulline | 1 | 2008 | 2 | 0.020 |
Why?
|
| Workload | 1 | 2009 | 30 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 23 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 45 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2009 | 115 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Social Environment | 1 | 2009 | 90 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 31 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 252 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2008 | 39 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2008 | 76 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2007 | 14 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2006 | 22 | 0.020 |
Why?
|
| Education, Nursing, Associate | 1 | 2006 | 1 | 0.020 |
Why?
|
| Helping Behavior | 1 | 2006 | 2 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 673 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2006 | 25 | 0.020 |
Why?
|
| Affect | 1 | 2006 | 26 | 0.020 |
Why?
|
| Catalase | 1 | 2006 | 1 | 0.020 |
Why?
|
| Glutathione Reductase | 1 | 2006 | 1 | 0.020 |
Why?
|
| Swimming | 1 | 2006 | 1 | 0.020 |
Why?
|
| alpha-Tocopherol | 1 | 2006 | 1 | 0.020 |
Why?
|
| Educational Status | 1 | 2007 | 205 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2006 | 8 | 0.020 |
Why?
|
| Rats | 1 | 2006 | 29 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2006 | 102 | 0.020 |
Why?
|
| Antioxidants | 1 | 2006 | 40 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2006 | 22 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2006 | 32 | 0.020 |
Why?
|
| Creatinine | 1 | 2006 | 65 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2006 | 58 | 0.020 |
Why?
|
| Cholesterol | 1 | 2006 | 112 | 0.020 |
Why?
|
| Vaccines, Inactivated | 1 | 2005 | 70 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2006 | 106 | 0.020 |
Why?
|
| Population | 1 | 2004 | 3 | 0.020 |
Why?
|
| Life Tables | 1 | 2004 | 11 | 0.020 |
Why?
|
| Office Visits | 1 | 2005 | 86 | 0.010 |
Why?
|
| Health Services Research | 1 | 2005 | 264 | 0.010 |
Why?
|
| Lipoproteins, VLDL | 1 | 2002 | 1 | 0.010 |
Why?
|
| Apolipoproteins B | 1 | 2002 | 8 | 0.010 |
Why?
|
| Body Height | 1 | 2002 | 62 | 0.010 |
Why?
|
| Body Weight | 1 | 2002 | 223 | 0.010 |
Why?
|